We specialize in developing and applying a variety of high-throughput, systems-based techniques, and use these in a disease-agnostic way. We believe that technology, and the data derived from it, will be key to tackle some of the world’s biggest biomedical problems, including cancer, infectious diseases, psychiatric disorders, tauophathies and heart disease. The experimental and computational tools we develop and apply include proteomics techniques like affinity purification with mass spectrometry (AP-MS), post-translational modification (PTM) profiling, cross-linking mass spectrometry (XL-MS), Ascorbate Peroxidase proximity labeling mass spectrometry (APEX-MS), and quantitative mass spectrometry, as well as functional genomics techniques like CRISPR/Cas9 editing, genetic interaction (GI) mapping, pooled and/or arrayed small RNA interference (RNAi) screening, next-generation sequencing, and computational tools to analyze and interpret the data resulting from these various technologies.